Age and Gender Could Factor into Advanced Renal Cell Carcinoma Outcomes

Video

Many factors impact outcomes in patients with advanced renal cell carcinoma, but recent findings suggest a patient’s age and gender are perhaps more important than previously realized.

In an interview with CURE®’s sister publication, OncLive®, McKay, who is an assistant professor of medicine and medical oncologist at the University of California, San Diego, explained how the biologic differences in the genetic profiles of men and women could impact the efficacy of certain treatments, and touched on how the toxicities that some patients experience could vary between younger and older patients.

Transcription:

There is a growing body of evidence that suggests that age and gender play a role in cancer outcomes, and there are multiple factors for this.

They could be biologic, (with) different genetic profiles for men and women and younger and elderly individuals. There's different chemical kinetics, for example, how we process different drugs may be processed differently in men versus women and also based on different ethnicities and presence of different enzymes that help with drug metabolism. We (also) know that toxicity patterns are different between younger and older individuals and male and female patients.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey. If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key. “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained. READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Related Content
Image of the FDA's logo on a blue abstract background.

FDA to Review Injectable Opdivo for All Approved Indications

May 8th 2024
Article

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

Read More

Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

January 30th 2024
Podcast

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

Listen

Image of a doctor holding a graphic of kidneys.

Postsurgical Keytruda Improves Survival in Clear Cell Kidney Cancer

April 18th 2024
Article

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy.

Read More

cancer horizons podcast logo

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

December 20th 2023
Podcast

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

Listen

Image of two kidneys.

Race Associated With Kidney Cancer Survival Disparities

March 28th 2024
Article

Across disease stages, Black patients with renal cell carcinoma experience worse survival outcomes than White patients, research has shown.

Read More

Image of a doctor holding an image of kidneys.

Radiotherapy A Noninvasive Option for Patients With Kidney Cancer

March 27th 2024
Article

Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.

Read More